These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26914078)

  • 1. [Recommendations for palivizumab use. Update 2015].
    ; Fernández Jonusas S; Albas Maubett D; Satragno D; Cattaino A; Martin Alonso M; Rubio C; Nieto R; ; ; ; ; ; ;
    Arch Argent Pediatr; 2016 Feb; 114(1):84-8. PubMed ID: 26914078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007743. PubMed ID: 22336832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ; McKoy NA
    Cochrane Database Syst Rev; 2013 Jun; (6):CD007743. PubMed ID: 23737087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
    Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
    Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries.
    Luna MS; Manzoni P; Paes B; Baraldi E; Cossey V; Kugelman A; Chawla R; Dotta A; Rodríguez Fernández R; Resch B; Carbonell-Estrany X
    Paediatr Respir Rev; 2020 Feb; 33():35-44. PubMed ID: 31060948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
    Hussman JM; Li A; Paes B; Lanctôt KL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
    Reeves RM; van Wijhe M; Lehtonen T; Stona L; Teirlinck AC; Vazquez Fernandez L; Li Y; Osei-Yeboah R; Fischer TK; Heikkinen T; van Boven M; Bøås H; Donà D; Barbieri E; Campbell H;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S110-S116. PubMed ID: 35333332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C; Scott LJ; Plosker GL
    Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to the 2014 American Academy of Pediatrics palivizumab prophylaxis recommendations.
    Sierra CM; Park A; Eum E; Garcia G; Lopez M; Daniel SN; Bahjri K; Parbuoni KA
    Pediatr Pulmonol; 2021 May; 56(5):1121-1126. PubMed ID: 33314771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 19. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.